KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Evolent Health (EVH) Other Operating Expenses (2016 - 2025)

Evolent Health has reported Other Operating Expenses over the past 11 years, most recently at $1.2 million for Q3 2025.

  • For Q3 2025, Other Operating Expenses changed N/A year-over-year to $1.2 million; the TTM value through Dec 2025 reached -$676000.0, up 96.43%, while the annual FY2025 figure was -$676000.0, 96.43% up from the prior year.
  • Other Operating Expenses for Q3 2025 was $1.2 million at Evolent Health, up from -$1.9 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $392.1 million in Q2 2023 and troughed at -$18.9 million in Q4 2024.
  • A 5-year average of $109.4 million and a median of $1.2 million in 2025 define the central range for Other Operating Expenses.
  • Biggest five-year swings in Other Operating Expenses: soared 1666692.86% in 2022 and later crashed 1002.34% in 2024.
  • Year by year, Other Operating Expenses stood at -$18000.0 in 2021, then soared by 1432416.67% to $257.8 million in 2022, then plummeted by 99.19% to $2.1 million in 2023, then crashed by 1002.34% to -$18.9 million in 2024, then surged by 106.5% to $1.2 million in 2025.
  • Business Quant data shows Other Operating Expenses for EVH at $1.2 million in Q3 2025, -$1.9 million in Q1 2025, and -$18.9 million in Q4 2024.